×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
HALO – halozyme therapeutics, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
HALO
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
3/18
01:11 am
halo
Halozyme Therapeutics Touts $1.8B Revenue Outlook, ENHANZE Royalties and New Hypercon Deals at Conference [Yahoo! Finance]
Medium
Report
Halozyme Therapeutics Touts $1.8B Revenue Outlook, ENHANZE Royalties and New Hypercon Deals at Conference [Yahoo! Finance]
3/13
11:32 pm
halo
Halozyme Names Interim CFO As Investors Weigh Valuation And Recent Weakness [Yahoo! Finance]
Low
Report
Halozyme Names Interim CFO As Investors Weigh Valuation And Recent Weakness [Yahoo! Finance]
3/12
08:54 am
halo
Halozyme Appoints David Ramsay as Interim Chief Financial Officer [Yahoo! Finance]
Medium
Report
Halozyme Appoints David Ramsay as Interim Chief Financial Officer [Yahoo! Finance]
3/12
08:30 am
halo
Halozyme Appoints David Ramsay as Interim Chief Financial Officer
Medium
Report
Halozyme Appoints David Ramsay as Interim Chief Financial Officer
3/11
01:23 pm
halo
Halozyme Therapeutics, Inc. (HALO) Presents at The Citizens Life Sciences Conference 2026 Transcript [Seeking Alpha]
Low
Report
Halozyme Therapeutics, Inc. (HALO) Presents at The Citizens Life Sciences Conference 2026 Transcript [Seeking Alpha]
3/10
03:08 pm
halo
Halozyme Therapeutics, Inc. (HALO) Presents at Leerink Global Healthcare Conference 2026 Transcript [Seeking Alpha]
Low
Report
Halozyme Therapeutics, Inc. (HALO) Presents at Leerink Global Healthcare Conference 2026 Transcript [Seeking Alpha]
3/10
07:28 am
halo
Breakout Ventures Launches Fund III with $114M to Continue Building the Future Powered by Science [Yahoo! Finance]
Low
Report
Breakout Ventures Launches Fund III with $114M to Continue Building the Future Powered by Science [Yahoo! Finance]
3/6
08:19 am
halo
U.S. FDA Approves TECVAYLI® in Combination with DARZALEX FASPRO® for Relapsed/Refractory Multiple Myeloma [Yahoo! Finance]
Low
Report
U.S. FDA Approves TECVAYLI® in Combination with DARZALEX FASPRO® for Relapsed/Refractory Multiple Myeloma [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
2/17/2026
04:01 pm
halo
halozyme therapeutics, inc.
MISS
Report
-9.0%
halozyme therapeutics, inc.
11/3/2025
04:01 pm
halo
halozyme therapeutics, inc.
BEAT
Report
2.8%
halozyme therapeutics, inc.
8/5/2025
04:01 pm
halo
halozyme therapeutics, inc.
BEAT
Report
2.4%
halozyme therapeutics, inc.
5/6/2025
04:01 pm
halo
halozyme therapeutics, inc.
BEAT
Report
18.1%
halozyme therapeutics, inc.
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
3/12
08:32 am
halo
Form 8-K HALOZYME THERAPEUTICS, For: Mar 12
Medium
Report
Form 8-K HALOZYME THERAPEUTICS, For: Mar 12
3/10
07:19 pm
halo
Form 4 HALOZYME THERAPEUTICS, For: Mar 09 Filed by: Caudill Cortney
Low
Report
Form 4 HALOZYME THERAPEUTICS, For: Mar 09 Filed by: Caudill Cortney
3/10
04:05 pm
halo
Form 144 HALOZYME THERAPEUTICS, Filed by: Caudill Cortney
Low
Report
Form 144 HALOZYME THERAPEUTICS, Filed by: Caudill Cortney
3/9
04:18 pm
halo
Form 144 HALOZYME THERAPEUTICS, Filed by: Caudill Cortney
Low
Report
Form 144 HALOZYME THERAPEUTICS, Filed by: Caudill Cortney
3/4
06:56 pm
halo
Form 4 HALOZYME THERAPEUTICS, For: Mar 02 Filed by: Torley Helen
Medium
Report
Form 4 HALOZYME THERAPEUTICS, For: Mar 02 Filed by: Torley Helen
2/24
06:19 pm
halo
Form 4 HALOZYME THERAPEUTICS, For: Feb 20 Filed by: Caudill Cortney
Low
Report
Form 4 HALOZYME THERAPEUTICS, For: Feb 20 Filed by: Caudill Cortney
2/24
06:16 pm
halo
Form 4 HALOZYME THERAPEUTICS, For: Feb 20 Filed by: Snyder Mark Howard
Low
Report
Form 4 HALOZYME THERAPEUTICS, For: Feb 20 Filed by: Snyder Mark Howard
2/24
06:15 pm
halo
Form 4 HALOZYME THERAPEUTICS, For: Feb 20 Filed by: LaBrosse Nicole
Low
Report
Form 4 HALOZYME THERAPEUTICS, For: Feb 20 Filed by: LaBrosse Nicole
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
11/12
Form 8-K/A HALOZYME THERAPEUTICS, For: Oct 30
21.4%
11/5 Halozyme Therapeutics, Inc. (NASDAQ: HALO) was upgraded by analysts at Barclays PLC from an "underweight" rating to an "equal weight" rating. They now have a $16.00 price target on the stock, down previously from $17.00. 10.6%
5/1 FDA OKs subcutaneous version of J&J's Darzalex [Seeking Alpha] 8.1%
3/20 Form DEFA14A HALOZYME THERAPEUTICS, 8.0%
1/9 Halozyme Therapeutics, Inc. (NASDAQ: HALO) was upgraded by analysts at BMO Capital Markets from a "market perform" rating to an "outperform" rating. 8.0%
4/3 Form 4 HALOZYME THERAPEUTICS, For: Apr 01 Filed by: Sun Elaine D 6.2%
1/14 Halozyme Provides 2020 Business Update And Financial Guidance 5.9%
1/8 Halozyme Therapeutics, Inc. (NASDAQ: HALO) is now covered by analysts at Goldman Sachs Group Inc. They set a "buy" rating on the stock. 5.4%
3/19 Form 4 HALOZYME THERAPEUTICS, For: Mar 19 Filed by: Kelley Kenneth J 4.5%
11/13 Halozyme Therapeutics, Inc. Announces Pricing of Private Offering of $400 Million of Convertible Senior Notes due 2024 4.5%
11/5 Halozyme Therapeutics, Inc. (NASDAQ: HALO) was upgraded by analysts at Barclays PLC from an "underweight" rating to an "equal weight" rating. They now have a $16.00 price target on the stock, down previously from $17.00. 10.6%
5/1 FDA OKs subcutaneous version of J&J's Darzalex [Seeking Alpha] 8.1%
3/20 Form DEFA14A HALOZYME THERAPEUTICS, 8.0%
1/9 Halozyme Therapeutics, Inc. (NASDAQ: HALO) was upgraded by analysts at BMO Capital Markets from a "market perform" rating to an "outperform" rating. 8.0%
4/3 Form 4 HALOZYME THERAPEUTICS, For: Apr 01 Filed by: Sun Elaine D 6.2%
1/14 Halozyme Provides 2020 Business Update And Financial Guidance 5.9%
1/8 Halozyme Therapeutics, Inc. (NASDAQ: HALO) is now covered by analysts at Goldman Sachs Group Inc. They set a "buy" rating on the stock. 5.4%
3/19 Form 4 HALOZYME THERAPEUTICS, For: Mar 19 Filed by: Kelley Kenneth J 4.5%
11/13 Halozyme Therapeutics, Inc. Announces Pricing of Private Offering of $400 Million of Convertible Senior Notes due 2024 4.5%
TOP News Decliners
2/27
argenx SE (ARGX) Q4 2019 Earnings Call Transcript [The Motley Fool]
-4.5%
4/3 Halozyme Announces Change Of Location Of Annual Stockholders' Meeting -4.4%
2/26 Halozyme Therapeutics To Present At The Cowen 40th Annual Health Care Conference -4.3%
5/13 Halozyme To Participate In Bank of America Merrill Lynch Health Care Conference 2019 -4.2%
8/8 Halozyme Therapeutics, Inc. (NASDAQ: HALO) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. -3.9%
8/6 Halozyme Reports Second Quarter 2019 Results -3.2%
9/4 Form 8-K HALOZYME THERAPEUTICS, For: Sep 04 -3.2%
2/25 Halozyme Therapeutics, Inc. (NASDAQ: HALO) had its price target lowered by analysts at JPMorgan Chase & Co. from $24.00 to $22.00. They now have an "overweight" rating on the stock. -3.0%
7/19 Halozyme Announces Janssen Submits Extension Application To European Medicines Agency For Subcutaneous Formulation Of DARZALEX® Utilizing ENHANZE® Technology -3.0%
7/3 Form SC 13D/A HALOZYME THERAPEUTICS Filed by: KIRK RANDAL J -2.0%
4/3 Halozyme Announces Change Of Location Of Annual Stockholders' Meeting -4.4%
2/26 Halozyme Therapeutics To Present At The Cowen 40th Annual Health Care Conference -4.3%
5/13 Halozyme To Participate In Bank of America Merrill Lynch Health Care Conference 2019 -4.2%
8/8 Halozyme Therapeutics, Inc. (NASDAQ: HALO) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. -3.9%
8/6 Halozyme Reports Second Quarter 2019 Results -3.2%
9/4 Form 8-K HALOZYME THERAPEUTICS, For: Sep 04 -3.2%
2/25 Halozyme Therapeutics, Inc. (NASDAQ: HALO) had its price target lowered by analysts at JPMorgan Chase & Co. from $24.00 to $22.00. They now have an "overweight" rating on the stock. -3.0%
7/19 Halozyme Announces Janssen Submits Extension Application To European Medicines Agency For Subcutaneous Formulation Of DARZALEX® Utilizing ENHANZE® Technology -3.0%
7/3 Form SC 13D/A HALOZYME THERAPEUTICS Filed by: KIRK RANDAL J -2.0%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: